Collaboration Revenue: $13.8 million in the first quarter of 2025, a 21% increase from the fourth quarter of 2024. R&D Expenses: $22.8 million in Q1 2025, a 68% decrease compared to the same period in 2024, and a nearly 40% decrease compared to Q4 2024. SG&A Expenses: $57.6 million in the first quarter of 2025.
Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 21% increase from the fourth quarter Sustained growth in shipments to women with postpartum depression; Greater than 3,000 shipments in first quarter of 2025 (22% increase from fourth quarter) Cash, cash